Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 0.65 |
| ▸ | CYSLTR2 | Q9NS75 | 6/20 | 0.65 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7010321 | 0.95 | CYSLTR1 (0.60) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL7717062 | 0.94 | CYSLTR2 (0.59) | CYSLTR1CYSLTR2 | |
| SCHEMBL7008709 | 0.92 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL9827514 | 0.92 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL9827383 | 0.92 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL9034082 | 0.91 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL9821174 | 0.91 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL10420450 | 0.90 | CYSLTR1 (0.62) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL7005427 | 0.89 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL6088514 | 0.89 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4839369-A | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-06-13 | — | — | US | claimed |
| EP-0200101-A2 | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive aliments | USV PHARMACEUTICAL CORPORATION (US) | 1986-11-05 | — | — | EP | claimed |
| US-RE40558-E1 | Therapeutic uses of di-aryl acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| US-RE40558-E1 | Therapeutic uses of di-aryl acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| EP-0385662-B1 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LTD (GB) | 1995-12-13 | — | — | EP | disclosed |
| EP-0375452-B1 | Cycloalkane derivatives | ICI PLC (GB) | 1994-10-05 | — | — | EP | disclosed |
| US-4874769-A | LIPOXYGENASE INHIBITORS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-10-17 | — | — | US | disclosed |
| US-4839369-A | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-06-13 | — | — | US | disclosed |
| EP-0260305-A4 | QUINOLINYL ETHER TETRAZOLE AS AGENT FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS. | RORER INTERNAT OVERSEAS INC (US) | 1988-07-04 | — | — | EP | disclosed |
| EP-0260305-A1 | QUINOLINYL ETHER TETRAZOLE AS AGENT FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS. | RORER INT OVERSEAS (US) | 1988-03-23 | — | — | EP | disclosed |
| WO-1987005510-A1 | QUINOLINYL ETHER OR THIOETHER TETRAZOLES AS AGENTS FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1987-09-24 | — | — | WO | disclosed |
| EP-0200101-A2 | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive aliments | USV PHARMACEUTICAL CORPORATION (US) | 1986-11-05 | — | — | EP | disclosed |